RLYP Stock News 22.70 05/13/2014 19:38:07 Relypsa Inc (RLYP)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Relypsa Inc (RLYP) 22.70 $RLYP

Relypsa Announces Topline Results From Patiromer Phase 1 Onset-of-Action Study
GlobeNewswire - Mon May 12, 7:01AM CDT
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced topline results from its Phase 1 onset-of-action study of patiromer, the final clinical trial planned to support a New Drug Application (NDA), which the company expects to submit to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014. The study reached its primary endpoint in which an early onset of potassium lowering action was observed. Following the first dose of patiromer, reductions in mean serum potassium were observed at all examined time points, with statistical significance first demonstrated at the second measurement (7 hours post drug administration). Over the 48-hour treatment period, during which patiromer was dosed twice daily, the potassium lowering effect was sustained with a steady decline in mean serum potassium, with no loss of effect or rebound in mean potassium levels during night-time periods.

Relypsa Announces First Quarter 2014 Financial Results
GlobeNewswire - Wed May 07, 3:48PM CDT
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2014. Net loss for the first quarter 2014 was $16.1 million, or $0.54 per share, compared to $26.3 million, or $84.61 per share, for the comparable period in 2013.

Hypercholesterolemia - Pipeline Review, H1 2014: 22 Company and 41 Drug Profiled
M2 - Wed May 07, 9:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7sxbqm/hypercholesterolem) has announced the addition of the "Hypercholesterolemia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypercholesterolemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypercholesterolemia and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - Alnylam Pharmaceuticals, Inc. - Amgen Astellas BioPharma K.K. - Bristol-Myers Squibb Company - Catabasis Pharmaceuticals, Inc. - Dybly AG - Eli Lilly and Company - Esperion Therapeutics, Inc. - FORMAC Pharmaceuticals N.V. - Immune Response BioPharma, Inc. - Johnson & Johnson - LondonPharma Ltd - Lumena Pharmaceuticals, Inc. - Madeira Therapeutics - Merck & Co., Inc. - NanoForm Therapeutics Ltd. - Pfizer Inc. - Planet Biotechnology Inc. - Regeneron Pharmaceuticals, Inc. - Relypsa, Inc. - Santaris Pharma A/S - Serometrix, LLC - Zhejiang Hisun Pharmaceutical Co., Ltd. Drug Profiles: - anacetrapib - alirocumab - evolocumab - bococizumab - ETC-1002 - Alpha Cyclodextrin - evolocumab - BMS-770767 - bococizumab - LY-3015014 - CAT-2003 - SPC-4955 - MGL-3196 - ALN-PCS02 - SPC-5001 - BMS-962476 - ralpancizumab - BMS-852927 - fenofibrate - simvastatin - fluvastatin sodium - pravastatin sodium - LUM-002 - PF-06678552 - HS-25 - ALN-PCS02 - RLY-106 - atorvastatin calcium - 1D05-Fab - IR-1002 For more information visit http://www.researchandmarkets.com/research/7s...lesterolem

Relypsa to Present at Bank of America Merrill Lynch 2014 Health Care Conference
GlobeNewswire - Tue May 06, 9:16AM CDT
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that John Orwin, Chief Executive Officer, will present a corporate overview at the Bank of America Merrill Lynch Health Care Conference in Las Vegas on May 13, 2014 at 5:00 pm PT.

Relypsa, Inc. Announces Closing of Public Offering of Common Stock
GlobeNewswire - Wed Apr 16, 3:00PM CDT
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced the closing of its public offering of 4,130,611 shares of its common stock at a price to the public of $24.50 per share for gross proceeds of approximately $101 million, which includes the exercise in full by the underwriters of their option to purchase up to 538,775 additional shares of common stock. Relypsa estimates net proceeds from the offering to be approximately $94 million, after deducting underwriting discounts and commissions and estimated offering expenses.

Nasdaq stocks posting largest percentage decreases
AP - Tue Apr 15, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:

Relypsa, Inc. Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Thu Apr 10, 10:50PM CDT
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced the pricing of an underwritten public offering of 3,591,836 shares of its common stock at a price to the public of $24.50 per share for gross proceeds of approximately $88 million. Relypsa estimates net proceeds from the offering to be approximately $82 million, after deducting underwriting discounts and commissions and estimated offering expenses. In addition, Relypsa has granted the underwriters a 30-day option to purchase up to an additional 538,775 shares of common stock.

Relypsa, Inc. Announces Proposed Public Offering of Common Stock
GlobeNewswire - Tue Apr 08, 3:05PM CDT
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of $80 million. All of the shares of the common stock to be sold in the offering will be offered by Relypsa. In addition, Relypsa intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares sold. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Relypsa Names Sylvia R. Wheeler V.P. Investor Relations and Corporate Affairs
GlobeNewswire - Wed Apr 02, 8:43AM CDT
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced the appointment of Sylvia R. Wheeler to the position of Vice President, Investor Relations and Corporate Affairs. Ms. Wheeler, a veteran biopharmaceutical executive, joins Relypsa with over 20 years of experience in investor relations and corporate communications. In her new role, Ms. Wheeler will be a member of the leadership team and will report to John Orwin, President and Chief Executive Officer of Relypsa.

Weakness Seen in Relypsa (RLYP): Stock Plunges 19.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 7:42AM CDT
Relypsa (RLYP) fell over 19% in the last trading session amid high volumes, breaking its recent volatile trend as it is currently trading below the volatile price range of last one month.

Relypsa (RLYP) in Focus: Stock Adds 12.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 8:46AM CDT
Relypsa was a big mover last session, with shares rising over 12% on the day.

Rev Shark: A Messy Day of Action
at The Street - Wed Mar 19, 3:31PM CDT
A few minor changes to Fed policy were enough to spook the market.

Narrower-Than-Expected Loss at Relypsa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 8:20AM CDT
Relypsa reported a loss of 68 cents per share narrower than the Zacks Consensus Estimate of a loss of 74 cents.

Relypsa Announces Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Mon Mar 17, 3:26PM CDT
Relypsa, Inc. (Nasdaq: RLYP), a biopharmaceutical company, today reported financial results for the fourth quarter and year ended December 31, 2013.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI Search Is Squeezing Clicks, Not Killing Content Yet

Updated Category News Views 77

A search result that answers the question before earning a click is a nasty little disruption, and marketers are plainly feeling around for solid ground. Goodfirms surveyed 192 content marketing professionals for its 2026 Content Engagement Metrics report, and the headline is more resilient than the prevailing panic: 66.3% said organic website traffic grew over the prior...

Continue Reading
Subaru's 650-Car Anniversary Bet Is Delightfully Small

Updated Category News Views 119

Gold brake calipers may sound like a fussy correction, yet that little detail tells you exactly who Subaru is trying to please. The company has revised its announcement for the 2027 WRX tS GD25 and BRZ tS ZC15, clarifying the anniversary-model names and changing the WRX description from red-painted to gold-painted Brembo calipers. Nobody should confuse a corrected paint...

Continue Reading
Somerville’s New Immersive Bet Has Room to Grow Locally

Updated Category News Views 172

A passcard, a hidden door, and 12,000 square feet of mischief have landed at Somernova. Edge of Elsewhere, the new flagship attraction from Boston-area creative studio Midnight Mansion, is open in Somerville’s Union Square as of November 18, 2026. It is part interactive art installation, part puzzle game, part physical story world. That sounds delightfully odd, which is...

Continue Reading
JOYY’s Ad Engine Gives Q3 Growth Some Real Teeth Now

Updated Category News Views 107

Three engines are finally pulling the cart at JOYY, and that is a far more interesting sight than another quarter of livestreaming merely holding together. The company reported third-quarter 2026 revenue of US$624.6 million, up 15.6% from a year earlier and 5.7% sequentially. Those are sturdy numbers, especially for a business that investors have long tended to box in as...

Continue Reading
J. Harmon Tests a Smarter Cannabis Accessory Niche

Updated Category News Views 53

Aisle Space Is the Real Prize Most cannabis accessory launches arrive dressed up like a gimmick and disappear before anyone has reordered them. J. Harmon has a more sensible target: give women products that look deliberate, work in everyday routines and do not demand designer-level money. The brand is set to debut at MJBizCon 2026 in Las Vegas, with LUVBUDS handling...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 102

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Chainlink, UBS Take $2 Trillion Notes Toward Onchain

Updated Category News Views 9

Paperwork is a lousy moat when a bank can automate the mess. Chainlink and UBS are putting that proposition to work in structured notes, a market with more than $2 trillion in outstanding notional and, frankly, an awful lot of operational clutter. Their production solution uses the Chainlink Runtime Environment, or CRE, to connect UBS systems, smart contracts, market data...

Continue Reading
Resolve Adds Cahaba in Birmingham Pain-Care Expansion

Updated Category News Views 226

Pain-care consolidation has a peculiar way of looking tidy in a release and messy in the real world. Resolve Pain Solutions announced on November 18, 2026, that it has acquired Cahaba Pain and Spine Care, an established provider serving greater Birmingham, Alabama. On its face, this is a straightforward expansion move: buy a respected local practice, retain its physician...

Continue Reading
Arbor Realty's Loan Mess Meets a Dividend Shutdown

Updated Category News Views 89

A dividend suspension lands differently when the loan book is already coughing up smoke. Arbor Realty Trust’s latest disclosed numbers are not the sort that investors can shrug off as one ugly quarter and forget by Friday. The company reported a third-quarter 2026 GAAP net loss of $85.4 million, suspended its quarterly cash dividend effective immediately, and described...

Continue Reading
Colon Cleanse Advice Deserves a Careful Read First

Updated Category News Views 23

Wellness copy can sound harmless right up until it blurs comfort guidance with health guidance. HelloNation’s feature on what to expect after a colon cleanse, drawing on Suzanne Childre of Gentle Wellness Center in Santa Monica, lays out a fairly familiar recovery script: drink water, rest, eat lightly, expect some bowel changes, and do not panic over a little fatigue....

Continue Reading

Top 5 Most Recently Viewed Articles

RTX and Cebu Pacific Forge Strategic Engine Maintenance Alliance

Updated Category News Views 201

Strategic Partnership Between RTX and Cebu Pacific In an exciting development for aviation partnerships, Pratt & Whitney, an RTX (NYSE: RTX) business, and Cebu Pacific have entered into a comprehensive long-term agreement aimed at maintaining the efficiency and reliability of Cebu Pacific’s GTF engine fleet. This strategic collaboration underlines the critical role of...

Continue Reading
Hellenic Music Ensemble Embarks on North American Tour

Updated Category News Views 172

The Hellenic Music Ensemble's Exciting North American Tour The Hellenic Music Ensemble is set to take North American audiences on a mesmerizing journey through Greece's rich musical heritage in 2026. Led by the talented Natassa Bofiliou and Giannis Haroulis, alongside special guest star Judy Kuhn, this tour promises to be a landmark event. Celebrating Greek Composers This...

Continue Reading
University of Maryland's Groundbreaking Fundraising Initiative

Updated Category News Views 258

University of Maryland Launches Its Largest Fundraising Campaign The University of Maryland proudly announces its most ambitious fundraising endeavor to date, aimed at elevating education and research. Titled Forward: The University of Maryland Campaign for the Fearless, this initiative seeks to raise an impressive $2.5 billion. With the goal of advancing the university's...

Continue Reading
New Insights on Dowlais Group Plc's Recent Activity

Updated Category News Views 203

Understanding Recent Trading Disclosures by Dowlais Group Plc As the financial landscape continuously evolves, public disclosures play a crucial role in ensuring transparency, trust, and regulatory compliance. Dowlais Group Plc, a notable player in the market, recently had transaction disclosures that are vital for investors and stakeholders alike. The company's exemplary...

Continue Reading
Stock Market Updates: Gains, Losses, and Oil Inventory Trends

Updated Category News Views 142

Recent U.S. Stock Market Movements As the trading day nears its end, U.S. stock indices show promising trends, with the S&P 500 making notable gains recently. This uptrend reflects a resilient market which continues to respond positively amidst economic fluctuations. Key Market Index Performances On Thursday, the Dow Jones Industrial Average climbed by 0.24%, reaching...

Continue Reading